Moxy is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis.

Moxy is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Moxy to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

How it works

The Moxy procedure is simple and straightforward. Following vessel preparation to ensure a clear pathway, the Moxy balloon is delivered to the target lesion and inflated for a minimum of 30 seconds. During this time, paclitaxel is immediately transferred to the artery’s endoluminal surface. The balloon is then deflated and removed.

Over time, therapeutic drug levels are sustained in the deeper layers of the arterial wall but not in the endothelium, thereby allowing new endothelial cells to grow and re-line the lumen.

Science first

Clinical use of the device is supported by an extensive scientific foundation. In order to select the final Moxy formulation, over 250 different potential formulations were tested and evaluated. More than 40 pre-clinical studies were conducted to evaluate safety and efficacy. Additionally, Lutonix has completed three human clinical trials studying the use of the Moxy drug-coated balloon catheter in both coronary and peripheral arteries.